Eric Joseph
Stock Analyst at JP Morgan
(2.02)
# 3,041
Out of 5,157 analysts
124
Total ratings
38.1%
Success rate
-6.05%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.45 | +218.84% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $28.05 | +74.69% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $26.08 | +76.38% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $81.52 | -21.49% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $4.96 | +41.13% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.83 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $10.80 | -35.19% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $65.67 | +2.03% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.16 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.33 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.95 | +88.09% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $9.82 | +42.57% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $99.59 | -28.71% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $26.31 | +44.43% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $5.60 | +310.71% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $14.08 | +20.74% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $10.80 | +94.44% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.17 | -29.43% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.50 | +900.00% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.99 | +100.67% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $17.06 | -35.52% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $25.14 | +297.77% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.73 | +83.15% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.10 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $46.78 | -76.49% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $26.96 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $8.75 | +1,271.43% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.57 | +3,863.01% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.93 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.56 | +476.92% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.40 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.25 | +1,766.67% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.68 | +253.26% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.41 | +2,586.86% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.45
Upside: +218.84%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $28.05
Upside: +74.69%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $26.08
Upside: +76.38%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $81.52
Upside: -21.49%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $4.96
Upside: +41.13%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.83
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $10.80
Upside: -35.19%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $65.67
Upside: +2.03%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.95
Upside: +88.09%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $9.82
Upside: +42.57%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $99.59
Upside: -28.71%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $26.31
Upside: +44.43%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $5.60
Upside: +310.71%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $14.08
Upside: +20.74%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $10.80
Upside: +94.44%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $14.17
Upside: -29.43%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.50
Upside: +900.00%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.99
Upside: +100.67%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $17.06
Upside: -35.52%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $25.14
Upside: +297.77%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.73
Upside: +83.15%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $6.10
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $46.78
Upside: -76.49%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $26.96
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $8.75
Upside: +1,271.43%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.57
Upside: +3,863.01%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $11.93
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.56
Upside: +476.92%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.40
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.25
Upside: +1,766.67%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.68
Upside: +253.26%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.41
Upside: +2,586.86%